Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) PT Raised to $355 at Leerink Partners
October 25, 2017 7:29 AM EDTLeerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
BMO Capital Upgrades Biogen (BIIB) to Outperform
October 25, 2017 1:01 AM EDTBMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $381.00 (from $382.00).
Analyst Ian Somaiya says the MS thesis is playing out. The analyst is not "calling the bottom on BIIB" noting the MS franchise estimate... More
SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel
October 24, 2017 11:58 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is an opportunity.
"Some SPINRAZA confusion based in flattish U.S. sales in the face of 75% patient number increase," Shrader commented. "We expect the 2Q revenue... More
